| Quarter | Prior | Estimate | Actual | Surprise | |
|---|---|---|---|---|---|
| Q4 2021 Pre-Market | EPS: REV: | ||||
| Q3 2021 Pre-Market | EPS: REV: | 8.84 3.376B | |||
| Q2 2021 Pre-Market | EPS: REV: | ||||
| Q1 2021 Pre-Market | EPS: REV: | 9.14 3.534B | |||
| Q4 2020 Pre-Market | EPS: REV: | 8.34 3.671B | 4.87 2.8B | 4.58 2.8526B | -5.95% 1.88% |
| Q3 2020 Pre-Market | EPS: REV: | 9.17 3.6B | 8.13 3.35B | 8.84 3.376B | 8.73% 0.78% |
| Q2 2020 Pre-Market | EPS: REV: | 9.15 3.617B | 8.04 3.44B | 10.26 3.682B | 27.61% 7.03% |
| Q1 2020 Pre-Market | EPS: REV: | 6.98 3.49B | 7.74 3.41B | 9.14 3.534B | 18.09% 3.64% |
| Q4 2019 Pre-Market | EPS: REV: | 6.99 3.526B | 7.92 3.52B | 8.34 3.671B | 5.3% 4.29% |
| Q3 2019 Pre-Market | EPS: REV: | 7.4 3.439B | 8.27 3.54B | 9.17 3.6B | 10.88% 1.69% |
Data powered by Benzinga Pro Calendars - Start your FREE TRIAL today!
News Coverage
- 5 Stocks To Watch For March 2, 2021
- Earnings Scheduled For March 2, 2021
- DraftKings Analysts Cheer Strong Q4, Sports Betting Growth And SBTech Integration
- Nio Reports Wider Q4 Loss Despite Revenues Topping $1B
- Travere Therapeutics: Q4 Earnings Insights
- Arcturus Therapeutics: Q4 Earnings Insights
- Hanger: Q4 Earnings Insights
- Recap: Xenon Pharmaceuticals Q4 Earnings
- Helios Technologies: Q4 Earnings Insights
- NIO: Q4 Earnings Insights
